HUTCHMED (China) Ltd (HCM): Capital Expenditures
$14.15M
Year ended 2025-12-31
-27.2%
3-year compound annual growth
+12.2%
5-year compound annual growth
+15.6%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.15M | -21.1% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $17.93M | -45.0% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $32.61M | -11.1% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $36.66M | +123.5% | 2025-03-19, From 2022-01-01 |
| 2021-12-31 | $16.40M | +106.3% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $7.95M | -7.2% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $8.56M | +34.6% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $6.36M | +26.8% | 2021-03-04, From 2018-01-01 |
| 2017-12-31 | $5.02M | +16.0% | 2020-03-03, From 2017-01-01 |
| 2016-12-31 | $4.33M | +30.2% | 2019-03-11, From 2016-01-01 |
| 2015-12-31 | $3.32M | -10.9% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $3.73M | n/a | 2017-03-13, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $14.15M | -21.1% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $14.15M | +41.1% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $954.0K | -3.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $1.10M | +17.6% |
| Insmed Inc (INSM) | 2025-12-31 | $32.56M | +48.5% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $214.0K | +375.6% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $480.0K | +77.8% |
Compare HCM, ORGO, MIRM, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗